YUTIQ (fluocinolone acetonide) by Eurofarma Laboratórios is corticosteroid hormone receptor agonists [moa]. First approved in 2018.
Drug data last refreshed 8h ago · AI intelligence enriched 5d ago
YUTIQ is a fluocinolone acetonide intravitreal implant approved in 2018 for chronic non-infectious uveitis affecting the posterior segment of the eye. It is a corticosteroid that works by agonizing corticosteroid hormone receptors to reduce inflammation. The implant provides sustained local drug delivery to the affected eye.
Approaching loss of exclusivity by January 2028 with minimal market penetration (17 Part D claims) suggests a niche product with limited commercial expansion opportunity and reduced team investment.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant
Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant
Worked on YUTIQ at Eurofarma Laboratórios? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in ~2 years — expect lifecycle management and generic defense hiring
With zero linked job openings and fast-approaching LOE, career opportunities on YUTIQ are severely constrained. Professionals joining this product should expect a defensive commercial posture focused on retention and margin protection rather than growth.